Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy (Q40824970)

24 September 2017

1 reference

title

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy (English)

1 reference

24 September 2017

1 reference

1 reference

J S Markowitz

1 reference

24 September 2017

C S Brown

series ordinal

1 reference

24 September 2017

T R Moore

series ordinal

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 January 1999

1 reference

Annals of Pharmacotherapy

24 September 2017

published in

1 reference

24 September 2017

1 reference

24 September 2017

1 reference

24 September 2017

page(s)

73-85

1 reference

Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia

24 September 2017

cites work

1 reference

Serotonin-dopamine interaction and its relevance to schizophrenia

21 January 2018

1 reference

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

21 January 2018

1 reference

5-HT2 antagonism and EPS benefits: is there a causal connection?

21 January 2018

1 reference

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

Atypical neuroleptics clozapine and thioridazine enhance amphetamine-induced stereotypy

21 January 2018

1 reference

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

21 January 2018

1 reference

Clozapine. A novel antipsychotic agent

21 January 2018

1 reference

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

21 January 2018

1 reference

Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of clozapine

21 January 2018

1 reference

Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists

21 January 2018

1 reference

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

21 January 2018

1 reference

Pharmacokinetics of clozapine and risperidone: a review of recent literature

21 January 2018

1 reference

Clozapine plasma level monitoring: current status

21 January 2018

1 reference

Risperidone: review and assessment of its role in the treatment of schizophrenia

21 January 2018

1 reference

Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia

21 January 2018

1 reference

A risk-benefit assessment of risperidone in schizophrenia

21 January 2018

1 reference

Radioreceptor binding profile of the atypical antipsychotic olanzapine

21 January 2018

1 reference

Metabolism of sertindole: identification of the metabolites in the rat and dog, and species comparison of liver microsomal metabolism.

21 January 2018

1 reference

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

A rating scale for drug-induced akathisia

21 January 2018

1 reference

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

21 January 2018

1 reference

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

21 January 2018

1 reference

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

21 January 2018

1 reference

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia

21 January 2018

1 reference

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.17215

1 reference

24 September 2017

1 reference